Variant report
Variant | esv3332322 |
---|---|
Chromosome Location | chr14:105014082-105016380 |
allele | n/a |
Outlinks | Ensembl   UCSC |
- TF binding region (count:0)
- CpG islands (count:0)
- Chromatin interactive region (count:3)
- LncRNA region (count:0)
- Mature miRNA region (count: 0)
- miRNA target sites (count:0)
No data |
No data |
(count:3 , 50 per page) page:
1
No data |
No data |
No data |
No data |
No. | Variant name | Chromosome position | Chromatin state | Related regulatory elements | Target genes | Extended variants | Associated traits |
---|---|---|---|---|---|---|---|
1 | rs146724104 | chr14:105014083-105014084 | Bivalent/Poised TSS Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
2 | rs34554982 | chr14:105014123-105014124 | Bivalent/Poised TSS Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
3 | rs139252616 | chr14:105014145-105014146 | Bivalent/Poised TSS Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
4 | rs555352417 | chr14:105014146-105014147 | Bivalent/Poised TSS Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
5 | rs34686607 | chr14:105014210-105014211 | Weak transcription Enhancers | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | n/a |
6 | rs540915800 | chr14:105014211-105014212 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
7 | rs375114164 | chr14:105014230-105014231 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
8 | rs35519712 | chr14:105014264-105014265 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
9 | rs564438156 | chr14:105014279-105014280 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
10 | rs184124266 | chr14:105014311-105014312 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
11 | rs60872733 | chr14:105014349-105014350 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
12 | rs189886705 | chr14:105014350-105014351 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
13 | rs34793922 | chr14:105014357-105014358 | Weak transcription Enhancers | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | n/a |
14 | rs529007899 | chr14:105014364-105014365 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
15 | rs144018354 | chr14:105014389-105014390 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
16 | rs559386943 | chr14:105014415-105014416 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
17 | rs528135575 | chr14:105014417-105014418 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
18 | rs372311647 | chr14:105014437-105014438 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
19 | rs113407556 | chr14:105014447-105014448 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
20 | rs571153115 | chr14:105014455-105014456 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
21 | rs114289890 | chr14:105014495-105014496 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
22 | rs550367996 | chr14:105014515-105014516 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
23 | rs570014028 | chr14:105014516-105014517 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
24 | rs535559253 | chr14:105014615-105014616 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
25 | rs555479487 | chr14:105014617-105014618 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
26 | rs34344768 | chr14:105014626-105014627 | Weak transcription Enhancers | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | n/a |
27 | rs534721759 | chr14:105014645-105014646 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
28 | rs557737932 | chr14:105014649-105014650 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
29 | rs146426417 | chr14:105014717-105014718 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
30 | rs543212633 | chr14:105014718-105014719 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
31 | rs563500014 | chr14:105014726-105014727 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
32 | rs181170836 | chr14:105014860-105014861 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
33 | rs201250914 | chr14:105014878-105014879 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
34 | rs9743695 | chr14:105014881-105014882 | Weak transcription Enhancers | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | n/a |
35 | rs28658432 | chr14:105014965-105014966 | Weak transcription Enhancers | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | n/a |
36 | rs112461551 | chr14:105014970-105014971 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
37 | rs28434197 | chr14:105014973-105014974 | Weak transcription Enhancers | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | n/a |
38 | rs9743984 | chr14:105014982-105014983 | Weak transcription Enhancers | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | n/a |
39 | rs186056825 | chr14:105015063-105015064 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
40 | rs12896097 | chr14:105015096-105015097 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
41 | rs12894943 | chr14:105015120-105015121 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
42 | rs4983404 | chr14:105015189-105015190 | Weak transcription Enhancers | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | n/a |
43 | rs564592198 | chr14:105015205-105015206 | Enhancers Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
44 | rs4983604 | chr14:105015214-105015215 | Enhancers Weak transcription | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | n/a |
45 | rs4983605 | chr14:105015215-105015216 | Enhancers Weak transcription | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | n/a |
46 | rs374640214 | chr14:105015236-105015237 | Enhancers Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
47 | rs533241513 | chr14:105015251-105015252 | Enhancers Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
48 | rs377736405 | chr14:105015257-105015258 | Enhancers Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
49 | rs567563285 | chr14:105015261-105015262 | Enhancers Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
50 | rs558625381 | chr14:105015271-105015272 | Enhancers Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
Disease | PMID | Source |
---|---|---|
Esophageal cancer | 21851588 | CNVD |
Ewing''s sarcoma | 21437220 | CNVD |
Glioblastoma multiforme | 21080181 | CNVD |
Retinoblastoma | 21504564 | CNVD |
High-proliferative meningiomas | 17937814 | CNVD |
Non-small cell lung cancer | 21044232 | CNVD |
Renal cell carcinoma | 19461508 | CNVD |
Cancer | 21637783 | CNVD |
Colorectal cancer | 20709793 | CNVD |
Melanoma | 18172304 | CNVD |
Esophageal squamous carcinoma | 21637470 | CNVD |
Medulloblastoma | 21979893 | CNVD |
Oral cancer | 21386901 | CNVD |
Endometrial cancer | 22040021 | CNVD |
Breast cancer | 21264507 | CNVD |
Hepatocellular carcinoma | 22174799 | CNVD |
Neuroblastoma | 19435921 | CNVD |
Colorectal cancer | 19359472 | CNVD |
Breast cancer | 17899364 | CNVD |
Gastrointestinal stromal cancer | 19259404 | CNVD |
Gastrointestinal stromal cancer | 17535989 | CNVD |
Monoclonal gammopathy of undetermined significance | 17077331 | CNVD |
Paraganglioma | 17535989 | CNVD |
Pulmonary chondroma | 17535989 | CNVD |
Gastrointestinal stromal cancer | 16982739 | CNVD |
Acute lymphoblastic leukemia | 20435627 | CNVD |
Gastrointestinal stromal cancer | 20818650 | CNVD |
Renal cell carcinoma | 21668985 | CNVD |
Chronic myeloid leukemia | 20724749 | CNVD |
Wilms tumour | 21544195 | CNVD |
Lung cancer | 18438408 | CNVD |
Hodgkin''s lymphoma | 17606441 | CNVD |
Colorectal cancer | 16774939 | CNVD |
Malignant mesothelioma | 18160781 | CNVD |
Pleural malignant mesothelioma | 18160781 | CNVD |
Neuroblastoma | 18923191 | CNVD |
Barrett''s syndrome | 19417022 | CNVD |
Chronic lymphocytic leukemia | 21546498 | CNVD |
cataract | 16735990 | CNVD |
Chronic lymphocytic leukemia | 20421269 | CNVD |
Acute lymphoblastic leukemia | 20067559 | CNVD |
Malignant peripheral nerve sheath tumor | 18522746 | CNVD |
small cell lung cancer | 20016488 | CNVD |
T-cell prolymphocytic leukemia | 19278963 | CNVD |
Developmental delay | 21147756 | CNVD |
Cancer | 20164920 | CNVD |
T-cell prolymphocytic leukemia | 17713554 | CNVD |
Basal cell lymphoma | 16317097 | CNVD |
Diffuse large b-cell lymphoma | 16317097 | CNVD |
Biliary cancer | 19435499 | CNVD |
Follicular lymphoma | 20505157 | CNVD |
Acute lymphoblastic leukemia | 20139093 | CNVD |
Hepatocellular carcinoma | 16750200 | CNVD |
Primary mediastinal b-cell lymphoma | 17728785 | CNVD |
Glioblastoma multiforme | 21922591 | CNVD |
Malignant fibrous histiocytomas | 21085701 | CNVD |
Ovarian cancer | 22174824 | CNVD |
Non-small cell lung cancer | 18320023 | CNVD |
Melanoma | 17363583 | CNVD |
Prostate cancer | 18632612 | CNVD |
Congenital heart defect | 22367666 | CNVD |
Developmental delay | 22367666 | CNVD |
Genitourinary abnormalities | 22367666 | CNVD |
Intellectual disability | 22367666 | CNVD |
Microcephaly | 22367666 | CNVD |
Muscularhypotonia | 22367666 | CNVD |
Ocular coloboma | 22367666 | CNVD |
Teratozoospermia | 22367666 | CNVD |
Cervical cancer | 21062161 | CNVD |
Non-syndromic sensorineural hearing loss | 15273396 | CNVD |
Breast cancer | 21990379 | CNVD |
Breast cancer | 16417655 | CNVD |
22q11 deletion syndrome | 22511897 | CNVD |
Cancer | 21129771 | CNVD |
Myelofibrosis | 22110671 | CNVD |
Glioblastoma multiforme | 22286061 | CNVD |
Primary central nervous system lymphoma | 21088137 | CNVD |
Schizophrenia | 21399695 | CNVD |
Intracranial ependymoma | 16609018 | CNVD |
Lung adenocarcinoma | 17086460 | CNVD |
Gastric adenocarcinoma | 19115996 | CNVD |
Acute lymphoblastic leukemia | 21098271 | CNVD |
14q deletion syndrome | 22511897 | CNVD |
Epilepsy | 22083797 | CNVD |
Urothelial carcinoma | 21177765 | CNVD |
Ovarian cancer | 21720365 | CNVD |
Cancer | 17440070 | CNVD |
Neurocytoma | 17123091 | CNVD |
Esophageal squamous carcinoma | 18405350 | CNVD |
Central neurocytomas | 17123091 | CNVD |
Acute lymphoblastic leukemia | 17315016 | CNVD |
Lung cancer | 17086460 | CNVD |
Mortal | 21835882 | CNVD |
Breast cancer | 21364760 | CNVD |
small cell lung cancer | 17426248 | CNVD |
Non-syndromic sensorineural hearing loss | 17122850 | CNVD |
Ependymoma | 20639864 | CNVD |
Schizophrenia | 23813976 | CNVD |
Breast cancer | 20932292 | CNVD |
low-grade B-cell lymphoma tumor | 18367492 | CNVD |
Non-syndromic sensorineural hearing loss | 18451855 | CNVD |
Ovarian cancer | 21781307 | CNVD |
Breast cancer | 22522925 | CNVD |
Pancreatic cancer | 17952125 | CNVD |
T-cell lymphomas | 22341440 | CNVD |
No. | Chromosome Location | Chromatin state | Cell line | Tissue |
---|---|---|---|---|
1 | chr14:105008000-105016600 | Enhancers | Fetal Brain Male | brain |
2 | chr14:105009800-105014600 | Weak transcription | ES-UCSF4 Cell Line | embryonic stem cell |
3 | chr14:105012600-105014800 | Weak transcription | Spleen | Spleen |
4 | chr14:105012600-105015400 | Weak transcription | iPS DF 6.9 Cell Line | embryonic stem cell |
5 | chr14:105012600-105016000 | Enhancers | iPS DF 19.11 Cell Line | embryonic stem cell |
6 | chr14:105012800-105014400 | Enhancers | Fetal Brain Female | brain |
7 | chr14:105013000-105016400 | Enhancers | Brain Germinal Matrix | brain |
8 | chr14:105014000-105014200 | Bivalent/Poised TSS | H1 Derived Mesenchymal Stem Cells | ES cell derived |
9 | chr14:105014400-105015400 | Weak transcription | Fetal Brain Female | brain |
10 | chr14:105014600-105014800 | Enhancers | ES-UCSF4 Cell Line | embryonic stem cell |
11 | chr14:105014800-105015000 | Enhancers | Spleen | Spleen |
12 | chr14:105014800-105015200 | Weak transcription | ES-UCSF4 Cell Line | embryonic stem cell |
13 | chr14:105015000-105015600 | Weak transcription | Spleen | Spleen |
14 | chr14:105015200-105015600 | Enhancers | ES-UCSF4 Cell Line | embryonic stem cell |
15 | chr14:105015200-105016000 | Enhancers | HUES6 Cell Line | embryonic stem cell |
16 | chr14:105015400-105015800 | Bivalent Enhancer | ES-I3 Cell Line | embryonic stem cell |
17 | chr14:105015400-105015800 | Enhancers | iPS-18 Cell Line | embryonic stem cell |
18 | chr14:105015400-105015800 | Enhancers | Fetal Brain Female | brain |
19 | chr14:105015400-105016000 | Enhancers | H1 Derived Neuronal Progenitor Cultured Cells | ES cell derived |
20 | chr14:105015400-105016000 | Enhancers | iPS-20b Cell Line | embryonic stem cell |
21 | chr14:105015400-105016200 | Enhancers | hESC Derived CD56+ Ectoderm Cultured Cells | ES cell derived |
22 | chr14:105015400-105016200 | Enhancers | iPS DF 6.9 Cell Line | embryonic stem cell |
23 | chr14:105015600-105015800 | Enhancers | Spleen | Spleen |
24 | chr14:105015600-105016400 | Enhancers | H1 Cell Line | embryonic stem cell |
25 | chr14:105015800-105016200 | Enhancers | ES-I3 Cell Line | embryonic stem cell |
26 | chr14:105015800-105020600 | Weak transcription | Fetal Brain Female | brain |
27 | chr14:105016000-105018200 | Weak transcription | iPS DF 19.11 Cell Line | embryonic stem cell |